CA2428693A1 - In vitro protein synthesis using glycolytic intermediates as an energy source - Google Patents

In vitro protein synthesis using glycolytic intermediates as an energy source Download PDF

Info

Publication number: CA2428693A1
Authority: CA; Canada
Prior art keywords: synthesis; pyruvate; reaction; atp; glucose
Prior art date: 2000-11-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002428693A

Other languages

English (en)

French (fr)

Inventor

Dong-Myung Kim

James Swartz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Leland Stanford Junior University

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-14

Filing date

2000-11-14

Publication date

2002-05-23

2000-11-14 Application filed by Individual filed Critical Individual

2002-05-23 Publication of CA2428693A1 publication Critical patent/CA2428693A1/en

Status Abandoned legal-status Critical Current

Links

230000002414 glycolytic effect Effects 0.000 title claims abstract description 18
238000000338 in vitro Methods 0.000 title abstract description 19
239000000543 intermediate Substances 0.000 title abstract description 14
230000014616 translation Effects 0.000 title description 67
238000001243 protein synthesis Methods 0.000 title description 58
238000003786 synthesis reaction Methods 0.000 claims abstract description 59
238000000034 method Methods 0.000 claims abstract description 51
230000015572 biosynthetic process Effects 0.000 claims abstract description 44
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 22
239000008103 glucose Substances 0.000 claims abstract description 22
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims abstract description 9
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 9
229920001184 polypeptide Polymers 0.000 claims abstract description 5
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 5
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 5
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical group CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 75
238000006243 chemical reaction Methods 0.000 claims description 71
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 67
229930029653 phosphoenolpyruvate Natural products 0.000 claims description 55
102000004190 Enzymes Human genes 0.000 claims description 46
108090000790 Enzymes Proteins 0.000 claims description 46
239000000284 extract Substances 0.000 claims description 39
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical group OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 claims description 25
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 claims description 25
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 21
241000588724 Escherichia coli Species 0.000 claims description 16
102000005548 Hexokinase Human genes 0.000 claims description 15
108700040460 Hexokinases Proteins 0.000 claims description 15
239000003112 inhibitor Substances 0.000 claims description 12
238000013519 translation Methods 0.000 claims description 10
108020004999 messenger RNA Proteins 0.000 claims description 9
229920002521 macromolecule Polymers 0.000 claims description 6
230000002503 metabolic effect Effects 0.000 claims description 5
108010031852 Pyruvate Synthase Proteins 0.000 claims description 4
230000004060 metabolic process Effects 0.000 claims description 4
235000006408 oxalic acid Nutrition 0.000 claims description 4
238000013518 transcription Methods 0.000 claims description 4
230000035897 transcription Effects 0.000 claims description 4
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims description 3
239000005516 coenzyme A Substances 0.000 claims description 3
229940093530 coenzyme a Drugs 0.000 claims description 3
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical group OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims 2
230000002950 deficient Effects 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 7
BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 abstract description 4
108020004707 nucleic acids Proteins 0.000 abstract description 4
102000039446 nucleic acids Human genes 0.000 abstract description 4
150000007523 nucleic acids Chemical class 0.000 abstract description 4
229920000642 polymer Polymers 0.000 abstract description 3
150000001720 carbohydrates Chemical class 0.000 abstract 1
235000014633 carbohydrates Nutrition 0.000 abstract 1
229940076788 pyruvate Drugs 0.000 description 73
108090000623 proteins and genes Proteins 0.000 description 64
DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 54
102000004169 proteins and genes Human genes 0.000 description 49
235000018102 proteins Nutrition 0.000 description 46
229950006238 nadide Drugs 0.000 description 32
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 31
210000004027 cell Anatomy 0.000 description 31
239000011541 reaction mixture Substances 0.000 description 30
229940024606 amino acid Drugs 0.000 description 25
235000001014 amino acid Nutrition 0.000 description 25
150000001413 amino acids Chemical class 0.000 description 25
230000008929 regeneration Effects 0.000 description 25
238000011069 regeneration method Methods 0.000 description 25
229940100228 acetyl coenzyme a Drugs 0.000 description 23
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 21
238000007792 addition Methods 0.000 description 16
239000012528 membrane Substances 0.000 description 14
239000003153 chemical reaction reagent Substances 0.000 description 13
230000000694 effects Effects 0.000 description 13
229910019142 PO4 Inorganic materials 0.000 description 12
230000001965 increasing effect Effects 0.000 description 12
239000010452 phosphate Substances 0.000 description 12
230000014509 gene expression Effects 0.000 description 11
239000000047 product Substances 0.000 description 11
LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 description 10
238000003556 assay Methods 0.000 description 9
229940039748 oxalate Drugs 0.000 description 9
238000007254 oxidation reaction Methods 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
108010042687 Pyruvate Oxidase Proteins 0.000 description 8
239000000463 material Substances 0.000 description 8
230000003647 oxidation Effects 0.000 description 8
239000000499 gel Substances 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
230000034659 glycolysis Effects 0.000 description 7
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 7
229940039790 sodium oxalate Drugs 0.000 description 7
210000004671 cell-free system Anatomy 0.000 description 6
238000011534 incubation Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000037361 pathway Effects 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
101150115222 HXK1 gene Proteins 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000003284 homeostatic effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
108020004566 Transfer RNA Proteins 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
239000006227 byproduct Substances 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000011777 magnesium Substances 0.000 description 4
229910052749 magnesium Inorganic materials 0.000 description 4
238000012423 maintenance Methods 0.000 description 4
238000001742 protein purification Methods 0.000 description 4
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
101710088194 Dehydrogenase Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
101710137500 T7 RNA polymerase Proteins 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
229940069446 magnesium acetate Drugs 0.000 description 3
235000011285 magnesium acetate Nutrition 0.000 description 3
239000011654 magnesium acetate Substances 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
210000003705 ribosome Anatomy 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
238000007086 side reaction Methods 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000013598 vector Substances 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
108091006112 ATPases Proteins 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
238000011537 Coomassie blue staining Methods 0.000 description 2
101710198385 Hexokinase-2 Proteins 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
108700023175 Phosphate acetyltransferases Proteins 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
239000012470 diluted sample Substances 0.000 description 2
108010008221 formate C-acetyltransferase Proteins 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
229910052816 inorganic phosphate Inorganic materials 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000005457 optimization Methods 0.000 description 2
238000012261 overproduction Methods 0.000 description 2
230000010627 oxidative phosphorylation Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000004952 protein activity Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001172 regenerating effect Effects 0.000 description 2
230000035806 respiratory chain Effects 0.000 description 2
101150025220 sacB gene Proteins 0.000 description 2
229940054269 sodium pyruvate Drugs 0.000 description 2
241000894007 species Species 0.000 description 2
229940063673 spermidine Drugs 0.000 description 2
229940063675 spermine Drugs 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
GXIURPTVHJPJLF-UWTATZPHSA-N 2-phosphoglycerate Natural products OC[C@H](C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UWTATZPHSA-N 0.000 description 1
GXIURPTVHJPJLF-UHFFFAOYSA-N 2-phosphoglyceric acid Chemical compound OCC(C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UHFFFAOYSA-N 0.000 description 1
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
108010092060 Acetate kinase Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241000186660 Lactobacillus Species 0.000 description 1
108010036940 Levansucrase Proteins 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
241000604136 Pediococcus sp. Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
102000005877 Peptide Initiation Factors Human genes 0.000 description 1
108010044843 Peptide Initiation Factors Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229940122277 RNA polymerase inhibitor Drugs 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
108020002494 acetyltransferase Proteins 0.000 description 1
102000005421 acetyltransferase Human genes 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 1
HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
238000003491 array Methods 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
238000010960 commercial process Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000012527 feed solution Substances 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
229940025237 fructose 1,6-diphosphate Drugs 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
229950010772 glucose-1-phosphate Drugs 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
229940039696 lactobacillus Drugs 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
150000002696 manganese Chemical class 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
235000013919 monopotassium glutamate Nutrition 0.000 description 1
230000035772 mutation Effects 0.000 description 1
KHPXUQMNIQBQEV-UHFFFAOYSA-L oxaloacetate(2-) Chemical compound [O-]C(=O)CC(=O)C([O-])=O KHPXUQMNIQBQEV-UHFFFAOYSA-L 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
238000002823 phage display Methods 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
230000003161 proteinsynthetic effect Effects 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000004064 recycling Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA002428693A 2000-11-14 2000-11-14 In vitro protein synthesis using glycolytic intermediates as an energy source Abandoned CA2428693A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2000/031449 WO2002040497A1 (en)	2000-11-14	2000-11-14	In vitro protein synthesis using glycolytic intermediates as an energy source

Publications (1)

Publication Number	Publication Date
CA2428693A1 true CA2428693A1 (en)	2002-05-23

Family

ID=21742001

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002428693A Abandoned CA2428693A1 (en)	2000-11-14	2000-11-14	In vitro protein synthesis using glycolytic intermediates as an energy source

Country Status (5)

Country	Link
EP (1)	EP1341802A4 (de)
JP (1)	JP2004513652A (de)
AU (1)	AU2001217678A1 (de)
CA (1)	CA2428693A1 (de)
WO (1)	WO2002040497A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004016778A1 (en)	2002-08-19	2004-02-26	The Board Of Trustees Of The Leland Stanford Junior University	Improved methods of in vitro protein synthesis
ES2527291T3 (es)	2004-03-11	2015-01-22	Genentech, Inc.	Proceso para la producción de polipéptidos
AU2012203817B2 (en) *	2004-03-11	2015-05-28	Genentech, Inc.	Process for producing polypeptides
WO2015025865A1 (ja) *	2013-08-21	2015-02-26	独立行政法人科学技術振興機構	酵素の保存液およびそれを用いた再構成型無細胞翻訳システム用反応液
EP3189162A1 (de) *	2014-09-02	2017-07-12	Pharmozyme, Inc.	Plattform zur genetischen detektion
US11951165B2 (en)	2016-12-30	2024-04-09	Vaxcyte, Inc.	Conjugated vaccine carrier proteins
MX2019007910A (es)	2016-12-30	2019-12-05	Sutrovax Inc	Conjugados de polipeptido-antigeno con aminoacidos no naturales.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4199498A (en) *	1975-07-15	1980-04-22	Snamprogetti S.P.A.	Macromolecularized adenine derivatives
JPS5564599A (en) *	1978-11-08	1980-05-15	Unitika Ltd	Adenosine triphosphate derivative
US5801006A (en) *	1997-02-04	1998-09-01	Specialty Assays, Inc.	Use of NADPH and NADH analogs in the measurement of enzyme activities and metabolites
JP4707237B2 (ja) *	1999-03-17	2011-06-22	ザボードオブトラスティーズオブザリーランドスタンフォードジュニアユニバーシティ	外因性アミノ酸および新規ａｔｐ再生システムを用いたインビトロ高分子生合成の方法

2000
- 2000-11-14 JP JP2002543505A patent/JP2004513652A/ja not_active Withdrawn
- 2000-11-14 AU AU2001217678A patent/AU2001217678A1/en not_active Abandoned
- 2000-11-14 EP EP00980413A patent/EP1341802A4/de not_active Withdrawn
- 2000-11-14 WO PCT/US2000/031449 patent/WO2002040497A1/en not_active Ceased
- 2000-11-14 CA CA002428693A patent/CA2428693A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2004513652A (ja)	2004-05-13
WO2002040497A1 (en)	2002-05-23
EP1341802A4 (de)	2004-09-08
EP1341802A1 (de)	2003-09-10
AU2001217678A1 (en)	2002-05-27

Legal Events

Date	Code	Title	Description
2005-01-10	EEER	Examination request
2006-11-14	FZDE	Discontinued

Publication	Publication Date	Title
US6337191B1 (en)	2002-01-08	Vitro protein synthesis using glycolytic intermediates as an energy source
EP1177311B1 (de)	2014-11-12	IN VITRO MAKROMOLEKüLBIOSYNTHESEVERFAHREN UNTER VERWENDUNG VON EXOGENEN AMINOSäUREN UND ATP-REGENERATIONSSYSTEM
US20020081660A1 (en)	2002-06-27	In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel ATP regeneration system
US6168931B1 (en)	2001-01-02	Enhanced in vitro synthesis of biological macromolecules using a novel ATP regeneration system
EP1539948B1 (de)	2009-10-14	Verbesserte verfahren zur in-vitro-proteinsynthese
CA2419996C (en)	2012-11-06	Enhanced in vitro synthesis of active proteins containing disulfide bonds
EP1649025B1 (de)	2012-01-11	Verfahren zur entkopplung des reaktionsmassstabs und der proteinsyntheseausbeute im diskontinuierlichen modus
US7871794B2 (en)	2011-01-18	Enhanced cell-free synthesis of active proteins containing disulfide bonds
AU2006259543B2 (en)	2012-05-24	Total amino acid stabilization during cell-free protein synthesis
Knapp et al.	2007	Cell‐free synthesis of proteins that require disulfide bonds using glucose as an energy source
KR20030031993A (ko)	2003-04-23	무세포 단백질 합성용 전사주형의 설계와 구축 및 이를이용하는 희석회분식 밀배아 무세포 단백질 합성방법
WO2002040497A1 (en)	2002-05-23	In vitro protein synthesis using glycolytic intermediates as an energy source
JP2017108740A (ja)	2017-06-22	改変型ｍｅｓｏ−ジアミノピメリン酸脱水素酵素
US8557558B2 (en)	2013-10-15	Compositions and methods of producing enterokinase in yeast
CN113493813A (zh)	2021-10-12	含外源镁离子的体外无细胞蛋白合成体系与试剂盒及其应用
Kim et al.	2006	Development of a rapid and productive cell-free protein synthesis system
CN113493801A (zh)	2021-10-12	一种含外源镁离子的体外无细胞蛋白合成体系和试剂盒及其应用
CN113403360B (zh)	2025-10-17	一种基于疏水界面的体外无细胞蛋白合成方法、d2p试剂盒及相关应用
US9803180B2 (en)	2017-10-31	S-adenosylmethionine (SAM) synthase variants for the synthesis of artificial cofactors
CN121022808A (zh)	2025-11-28	D-海因酶的突变体及其应用